Search
for
Sort by
Research 121–150 of 146
- Treating Alopecia Areata: Current Practices Versus New Directions
- Immunology of alopecia areata
- Patient’s experience with subcutaneous and oral methotrexate for the treatment of rheumatoid arthritis
- Hidradenitis Suppurativa and Comorbid Disorder Biomarkers, Druggable Genes, New Drugs and Drug Repurposing—A Molecular Meta-Analysis
- Exploring Mast Cell–CD8 T Cell Interactions in Inflammatory Skin Diseases
- The Scientific Legacy of Stephen Rothman
- Immune therapies for alopecia areata: evidence and new perspectives
- Cannabinoid Compounds as a Pharmacotherapeutic Option for the Treatment of Non-Cancer Skin Diseases
- Medical Dermatology
- Adverse Reactions to Biologic Medications Used in Allergy and Immunology Diseases
- The Impact of Immune-Modifying Treatments for Skin Diseases on the Immune Response to COVID-19 Vaccines: a Narrative Review
- Adipose-derived stem cells applied in skin diseases, wound healing and skin defects: a review
- Screening of dermatology drugs for aberrant use‐patterns: An application of epidemiologic estimates and measures of inequality in drug use
- Industry Updates from the Field of Stem Cell Research and Regenerative Medicine in December 2019
- New Modalities in the Treatment of Refractory Alopecia Areata
- The Immunological Intersection of Psoriasis and Autoimmune Diseases: Shared Pathways and Clinical Implications
- Repigmentation Competence in Vitiligo: Integrating Immune, Regulatory, Regenerative, and Microenvironmental Axes
- Plasma proteome–driven identification of druggable immune regulators of alopecia areata, validated by transcriptome and single-cell mapping
- Where is the data? Delayed and chronic irAE surveillance and management after cessation of ICIs: expert insights from SITC on survivorship care and the need for long-term data
- Pyroptosis in Alopecia Areata: Synthesizing Emerging Hypotheses and Charting a Path to New Therapies
- CGF therapy: bridging androgenetic alopecia observations to psoriasis treatment via IL-17 pathway
- Drug-Induced Hair Loss: Analysis of the Food and Drug Administration’s Adverse Events Reporting System Database
- Chemical Synthetic Disease Modifying Drugs (csDMARD) Used forRheumatoid Arthritis
- Application of the waiting time distribution in a nationwide screening of real‐world dermatology drug utilization for aberrant use patterns
- Alopecia Areata in Latin America: Where are We and Where are We Going?
- New Drugs for Alopecias
- Treatment of Generalized Lichen Planus With Alefacept
- Alefacept for Severe Alopecia Areata
- Alefacept for Alopecia Areata
- Alefacept for Severe Alopecia Areata: A Randomized, Double-blind, Placebo-Controlled Study